macrocycl peptide privilege scaffold drug develop constitute signifies portion drug market today field span infect disease oncology develop oral bioavail peptides remain challenge task howe macrocycl linear effect strategy improv membrane permeable proteolyt static oral bioavail overall druglik characters class advance solidphas peptide synthesis spp enable office construct peptidomimet library macrolactam perform resin solute phase primary goal review summary cyclohexapeptid use solutionphas methodology publish since also highlight broad applied rang natur product total synthetic methodology medicine chemistry analyst conform physiochem property 